Becton Dickinson and Co (NYSE:BDX) CEO Sells $3,814,133.40 in Stock

Becton Dickinson and Co (NYSE:BDX) CEO Vincent A. Forlenza sold 13,860 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $275.19, for a total transaction of $3,814,133.40. Following the completion of the transaction, the chief executive officer now owns 227,647 shares in the company, valued at $62,646,177.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of BDX stock traded up $0.24 on Friday, hitting $273.78. The company’s stock had a trading volume of 630,820 shares, compared to its average volume of 1,074,478. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.72 and a current ratio of 1.18. The stock’s 50 day moving average is $265.04 and its 200-day moving average is $255.28. Becton Dickinson and Co has a fifty-two week low of $221.47 and a fifty-two week high of $275.54. The company has a market capitalization of $73.94 billion, a PE ratio of 23.44, a PEG ratio of 1.95 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.52%. The business had revenue of $4.58 billion during the quarter, compared to analysts’ expectations of $4.57 billion. During the same quarter in the prior year, the business posted $2.93 earnings per share. Becton Dickinson and’s revenue was up 4.1% compared to the same quarter last year. On average, research analysts forecast that Becton Dickinson and Co will post 12.57 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Tuesday, December 10th were given a dividend of $0.79 per share. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date was Monday, December 9th. This represents a $3.16 annualized dividend and a yield of 1.15%. Becton Dickinson and’s dividend payout ratio is currently 27.05%.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its position in Becton Dickinson and by 0.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 34,250,739 shares of the medical instruments supplier’s stock worth $8,631,529,000 after purchasing an additional 131,536 shares during the period. Vanguard Group Inc. lifted its position in Becton Dickinson and by 2.3% during the second quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock worth $5,800,769,000 after purchasing an additional 520,350 shares during the period. Morgan Stanley lifted its position in Becton Dickinson and by 66.7% during the second quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock worth $1,231,621,000 after purchasing an additional 1,955,095 shares during the period. Bank of America Corp DE lifted its position in Becton Dickinson and by 4.1% during the second quarter. Bank of America Corp DE now owns 2,901,319 shares of the medical instruments supplier’s stock worth $731,162,000 after purchasing an additional 114,398 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in Becton Dickinson and by 33.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,152,328 shares of the medical instruments supplier’s stock worth $544,452,000 after purchasing an additional 543,512 shares during the period. 84.46% of the stock is owned by institutional investors and hedge funds.

Several research firms recently commented on BDX. Stifel Nicolaus upped their price target on shares of Becton Dickinson and from $275.00 to $295.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Barclays downgraded shares of Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 price target on the stock. in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Becton Dickinson and from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. Morgan Stanley upped their price target on shares of Becton Dickinson and from $261.00 to $287.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Finally, KeyCorp decreased their price target on shares of Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $277.70.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: S&P 500 Index

Insider Buying and Selling by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.